Ratings for 10x Genomics (NASDAQ:TXG) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 7 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 4 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of $20.36, a high estimate of $25.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 16.34% from the previous average price target of $17.50.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of 10x Genomics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Daniel Arias | Stifel | Raises | Buy | $25.00 | $20.00 |
| Dan Leonard | UBS | Raises | Neutral | $20.00 | $14.00 |
| Daniel Arias | Stifel | Raises | Buy | $20.00 | $15.00 |
| Dan Brennan | TD Cowen | Raises | Hold | $19.00 | $18.00 |
| Mike Kratky | Leerink Partners | Lowers | Market Perform | $20.00 | $22.00 |
| Mike Kratky | Leerink Partners | Raises | Market Perform | $22.00 | $20.00 |
| Mike Kratky | Leerink Partners | Raises | Market Perform | $20.00 | $15.00 |
| Dan Brennan | TD Cowen | Raises | Hold | $18.00 | $15.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $20.00 | $19.00 |
| Luke Sergott | Barclays | Raises | Overweight | $22.00 | $17.00 |
| Patrick Donnelly | Citigroup | Announces | Neutral | $18.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to 10x Genomics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of 10x Genomics's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of 10x Genomics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on 10x Genomics analyst ratings.
Get to Know 10x Genomics Better
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10x Genomics's Economic Impact: An Analysis
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: 10x Genomics's remarkable performance in 3M is evident. As of 31 December, 2025, the company achieved an impressive revenue growth rate of 0.61%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: 10x Genomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -9.79%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 10x Genomics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.06%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!